Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Elinzanetant led to a significantly lower frequency of vasomotor symptoms associated with endocrine therapy than placebo. (Funded by Bayer; OASIS-4 ClinicalTrials.gov number, NCT05587296.).

Bookmark

Cite This Study

Cardoso et al. (Mon,) studied this question.

synapsesocial.com/papers/69dcc97a7873f5f05b134159 https://doi.org/https://doi.org/10.1056/nejmoa2415566

Bookmark